Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Xeljanz
Tofacitinib is a small molecule Janus kinase (JAK) inhibitor, specifically targeting JAK1, JAK3, and to a lesser extent JAK2. It works by interfering with the intracellular signaling pathways involved in immune cell activation and inflammation. This makes it useful for treating conditions like rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis.
For the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis.
Serious infections and malignancies, including lymphoma, have been observed with tofacitinib. Increased risk of major adverse cardiovascular events (MACE) and thrombosis.
Outcome:
Increased risk of infection
Mechanism:
Immunosuppression
Outcome:
Increased risk of gastrointestinal bleeding
Mechanism:
Additive effects on GI mucosa
Outcome:
Decreased tofacitinib absorption
Mechanism:
Chelation
Most likely new formulation: Extended-release formulation (Year 2025, 80% confidence)
Based on current usage trends and safety profile, there is a 70% likelihood of continued FDA monitoring and potential label updates regarding cardiovascular risks.
Janus kinase (JAK) inhibitor, Immunosuppressant
Pyrrolopyrimidine